This was a randomized trial of first line monoclonal antibody therapy of CD20 positive non-Hodgkin's lymphoma (low grade) following recurrence or relapse following conventional therapy. Patients are randomized to Y902B8 vs. C2B8 to evaluate efficacy. To date we have treated 4 patients. 1 on the Y2B8 arm and 3 on the C2B8 arm. Preliminary individual outcome data reflects the anticipated response to the individual treatment options. The study has accrued its population and awaits analysis.
Showing the most recent 10 out of 570 publications